Frontiers in Pharmacology

OCT 23, 2026 · JOURNAL ARTICLE

Cost-effectiveness analysis of cetuximab for the treatment of head and neck cancers in India

Frontiers in Pharmacology

Background Head and neck cancers (HNC) comprise 5% of all malignancies worldwide. Cetuximab is the first targeted therapy to demonstrate a significant survival benefit in patients

OCT 23, 2026 · JOURNAL ARTICLE

Dementia-related risk associated with endocrine and targeted therapy strategies in breast cancer: a real-world pharmacovigilance analysis

Frontiers in Pharmacology

Background In clinical practice, adjuvant endocrine and targeted (ET) therapy strategies for hormone receptor-positive (HR+) breast cancer are constantly evolving. The long-term co

OCT 23, 2026 · JOURNAL ARTICLE

Immune-related adverse reactions across multiple systems in a non-small cell lung cancer patient induced by immune checkpoint inhibitors: a case report and literature review

Frontiers in Pharmacology

Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC), while overlapping multi-system immune-related adverse events

OCT 22, 2026 · JOURNAL ARTICLE

Natural products target the NRF2-ferroptosis axis in hepatocellular carcinoma: tumor sensitization versus hepatoprotection

Frontiers in Pharmacology

Hepatocellular carcinoma (HCC) remains a major cause of cancer mortality. First-line systemic therapy is now led by immune checkpoint inhibitor (ICI)-based regimens, notably atezol

OCT 22, 2026 · JOURNAL ARTICLE

CLDN18.2 in colorectal mucinous adenocarcinoma: a lineage-associated biomarker and emerging translational target

Frontiers in Pharmacology

Colorectal mucinous adenocarcinoma (CMA) is a histologically and molecularly distinct subtype of colorectal cancer (CRC), marked by abundant extracellular mucin, a predilection for

OCT 22, 2026 · JOURNAL ARTICLE

Molecularly guided pharmacotherapy for obesity: emerging targets, clinical efficacy, and personalized therapeutic approaches

Frontiers in Pharmacology

Obesity is a complex, chronic disease whose aetiology is complex and highly variable, and is linked to a network of neural, endocrine, adipose, genetic, epigenetic and metabolic pa

OCT 21, 2026 · JOURNAL ARTICLE

Eicosapentaenoic acid exhibits antitumor effects and synergistically enhances carboplatin sensitivity in endometrial cancer

Frontiers in Pharmacology

Background Obesity-related metabolic dysfunction and chronic inflammation are well-established drivers of the carcinogenesis and progression of endometrial cancer (EC). Eicosapenta

OCT 21, 2026 · JOURNAL ARTICLE

Pluronic F-127-functionalized magnetic ternary hybrid nanoparticles for co-delivery of paclitaxel and psoralen: a synergistic strategy to overcome multidrug resistance in triple-negative breast cancer

Frontiers in Pharmacology

A series of magnetic ternary hybrid nanoparticles were synthesized through the chemical integration of superparamagnetic iron oxide nanoparticles (SPIONs), poly (lactic-co-glycolic